➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Boehringer Ingelheim
Merck
McKesson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AG-348

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AG-348?

AG-348 is an investigational drug.

There have been 11 clinical trials for AG-348. The most recent clinical trial was a Phase 1 trial, which was initiated on May 25th 2018.

The most common disease conditions in clinical trials are Pyruvate Metabolism, Inborn Errors, Anemia, Hemolytic, Congenital Nonspherocytic, and Anemia, Hemolytic. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and [disabled in preview].

There are six US patents protecting this investigational drug and ninety-nine international patents.

Recent Clinical Trials for AG-348
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsAgios Pharmaceuticals, Inc.Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI)Phase 1
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007Agios Pharmaceuticals, Inc.Phase 3

See all AG-348 clinical trials

Clinical Trial Summary for AG-348

Top disease conditions for AG-348
Top clinical trial sponsors for AG-348

See all AG-348 clinical trials

US Patents for AG-348

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-348   Start Trial Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AG-348   Start Trial Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AG-348   Start Trial Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC (Cambridge, MA)   Start Trial
AG-348   Start Trial Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC (Cambridge, MA)   Start Trial
AG-348   Start Trial Predicting and treating diabetic complications Joslin Diabetes Center, Inc. (Boston, MA)   Start Trial
AG-348   Start Trial Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-348

Drugname Country Document Number Estimated Expiration Related US Patent
AG-348 Argentina 077292 2029-06-29   Start Trial
AG-348 Argentina 112803 2029-06-29   Start Trial
AG-348 Australia 2010266386 2029-06-29   Start Trial
AG-348 Brazil PI1011587 2029-06-29   Start Trial
AG-348 Canada 2766882 2029-06-29   Start Trial
AG-348 Canada 2944788 2029-06-29   Start Trial
AG-348 Chile 2011003350 2029-06-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Boehringer Ingelheim
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.